PPARG and metabolic syndrome: As an example, some of the lipid-lowering effects of PPARγ agonists, attributable to defects in fatty acid use or storage are only observed in the context of diabetes, but not in nondiabetic atherosclerotic models in which the dyslipidemia is caused, for example, by defective ApoE [92].